Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

121. Australian Asthma Handbook

Australian Asthma Handbook Australian Asthma Handbook | Australian Asthma Handbook Know what you're looking for? Australia's National Guidelines for Asthma Management The Australian Asthma Handbook provides best-practice, evidence-based guidance translated into practical advice for primary care health professionals. The Handbook is proudly published by Australia's lead asthma authority, the National Asthma Council Australia. 1 2 3 1 2 3 1 2 3 Australian Asthma Handbook v1.2 Version 1.2 (...) continues to set the standard for practical, evidence-based advice for primary care chronic disease management. Stay up to date Join our health professional community and stay informed on Handbook updates Disclaimer The Australian Asthma Handbook is the national guidelines for asthma management in primary care. It has been developed for use by Australian health professionals. Use of this website is subject to disclaimers that we encourage you to . © National Asthma Council Australia 2017 site by

Clinical Practice Guidelines Portal2017

123. Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma.

Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma. Importance: Although asthma is a chronic disease, the expected rate of spontaneous remissions of adult asthma and the stability of diagnosis are unknown. Objective: To determine whether a diagnosis of current asthma could be ruled out and asthma medications safely stopped in randomly selected adults with physician-diagnosed asthma. Design, Setting, and Participants: A prospective, multicenter cohort study was conducted in 10 (...) Canadian cities from January 2012 to February 2016. Random digit dialing was used to recruit adult participants who reported a history of physician-diagnosed asthma established within the past 5 years. Participants using long-term oral steroids and participants unable to be tested using spirometry were excluded. Information from the diagnosing physician was obtained to determine how the diagnosis of asthma was originally made in the community. Of 1026 potential participants who fulfilled eligibility

JAMA2017

124. Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks

Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks

California Technology Assessment Forum2017

125. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma 27811070 2016 11 04 2017 02 24 1399-3003 49 1 2017 Jan The European respiratory journal Eur. Respir. J. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. 1601100 10.1183/13993003.01100-2016 We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents (...) numerical improvements in peak FEV1(0-3h) response, compared with placebo (90 mL; p=0.104), and significant improvements were observed with tiotropium 2.5 µg (111 mL; p=0.046). Numerical improvements in trough FEV1 response and asthma control were observed with both tiotropium doses, compared with placebo. The safety and tolerability of tiotropium were comparable with those of placebo.Once-daily tiotropium Respimat add-on to ICS plus one or more controller therapies in adolescents with severe

EvidenceUpdates2017

127. PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term a cluster randomised controlled trial and economic evaluation

PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term a cluster randomised controlled trial and economic evaluation PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term a cluster randomised controlled trial and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you (...) requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} A medication reminder letter sent in July from general practitioners to parents/carers of school-age children with asthma did not reduce unscheduled contacts in September; but there appeared to be later effects and cost savings. {{author}} {{($index

NIHR HTA programme2017

128. Asthma

Asthma Asthma - NICE CKS Clinical Knowledge Summaries Share Asthma: Summary Asthma is a chronic inflammatory condition of the airways. The airways are hyper-responsive and constrict easily in response to a wide range of stimuli. This may result in coughing, wheezing, chest tightness, and shortness of breath. Narrowing of the airways is usually reversible (either spontaneously or with medication), leading to intermittent symptoms, but in some people with chronic asthma, the inflammation may lead (...) to irreversible airflow obstruction. Asthma is a common condition. A report by Asthma UK states that 5.4 million people in the UK have asthma. The probability of someone having asthma is increased if they have: Wheeze, breathlessness, chest tightness, and cough, particularly if symptoms are worse at night and in the early morning; occur in response to exercise, allergen exposure, and cold air; occur after taking non-steroidal anti-inflammatory drugs, or beta-blockers; occur in the absence of an upper

NICE Clinical Knowledge Summaries2017

129. An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children.

An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. BACKGROUND: Increasing evidence suggests that patterns of T-cell immunity to inhalant allergens in genetically diverse human populations are more heterogeneous than previously assumed, and that covert differences in expression patterns might underlie variations in airway disease phenotypes. We tested this proposition in a community sample (...) of children. METHODS: We analysed data from 172 individuals who had been recruited antenatally to a longitudinal birth cohort study. Of the 194 birth cohort participants, data from the 147 probands (age range 8.6-13.5 years) who consented to blood collection were included along with data from 25 consenting siblings (mean age 11 years [range 7.4-17.4]). We ascertained clinical phenotypes related to asthma and allergy. We measured T-cell responses to allergens and mitogens, together with blood eosinophils

Lancet2017

130. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad range of anti-inflammatory effects on various key effector cells involved in asthma and chronic obstructive pulmonary disease (COPD). The therapeutic ratio for PDE4 inhibitors is thought to be determined by selectivity on receptor subtypes for relative effects on PDE4B (anti-inflammatory (...) have shown variable but significant effects on exacerbations and quality of life, with small improvements in measures of pulmonary function. Roflumilast has a better safety and tolerability profile than cilomilast, with the main adverse effects being nausea, diarrhoea, and abdominal pain. Roflumilast also has activity in asthma as assessed by its attenuation of allergen and exercise challenges, and it shows clinical efficacy equivalent to that of beclomethasone dipropionate 400 mug daily

Lancet2017

131. Severe asthma treatment: need for characterising patients.

Severe asthma treatment: need for characterising patients. CONTEXT: Asthma is readily diagnosed in most cases and usually responds to inhaled corticosteroids with or without long-acting beta agonists, theophyllines, or leukotriene-receptor antagonists, adjusted stepwise according to symptoms and lung function. However, up to 40% of adult patients with asthma remain symptomatic, and up to 5% have difficult-to-control asthma despite multiple therapies. It is suggested that higher doses of inhaled (...) steroids with long-acting beta2 agonists should be used for total control of symptoms; and anti-IgE therapy is newly licensed in the USA. However, difficult-to-control asthma is complex and multifactorial, and is often not due to severe or therapy-resistant asthma. STARTING POINT: Last year saw encouraging reports on omalizumab (anti-IgE therapy) in severe allergic asthma, by Stephen Holgate, Jon Ayres, and their respective colleagues (Clin Exp Allergy 2004; 34: 632-38; Allergy 2004; 59: 701-08

Lancet2017

132. Asthma: diagnosis, monitoring and chronic asthma management.

Asthma: diagnosis, monitoring and chronic asthma management. Asthma: diagnosis, monitoring and chronic asthma management. | National Guideline Clearinghouse success fail May JUN Jul 09 2017 2018 2019 08 Jun 2018 - 09 Jun 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group (...) at . TIMESTAMPS Search Sign In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011311 2017 Nov 29 NEATS Assessment Asthma: diagnosis, monitoring and chronic asthma management. National Guideline Centre. Asthma: diagnosis

National Guideline Clearinghouse (partial archive)2017

133. Adult asthma care: promoting control of asthma, second edition.

Adult asthma care: promoting control of asthma, second edition. Adult asthma care: promoting control of asthma, second edition. | National Guideline Clearinghouse success fail JUN 10 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group (...) at . TIMESTAMPS Search Sign In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011235 2017 May NEATS Assessment Adult asthma care: promoting control of asthma, second edition. Registered Nurses' Association of Ontario

National Guideline Clearinghouse (partial archive)2017

134. Randomised controlled trial: Possible protective effect of prenatal omega-3 long-chain polyunsaturated fatty acids supplementation on persistent wheeze and asthma in early childhood

Randomised controlled trial: Possible protective effect of prenatal omega-3 long-chain polyunsaturated fatty acids supplementation on persistent wheeze and asthma in early childhood Possible protective effect of prenatal omega-3 long-chain polyunsaturated fatty acids supplementation on persistent wheeze and asthma in early childhood | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Possible protective effect of prenatal omega-3 long-chain polyunsaturated fatty acids supplementation on persistent wheeze and asthma in early childhood Article Text Therapeutics

Evidence-Based Medicine (Requires free registration)2017

135. Adult Asthma Care: Promoting Control of Asthma

Adult Asthma Care: Promoting Control of Asthma Adult Asthma Care: Promoting Control of Asthma | Registered Nurses' Association of Ontario l’Association des infirmières et infirmiers autorisés de l’Ontario Speaking out for nursing. Speaking out for health. » » Adult Asthma Care: Promoting Control of Asthma Type of Guideline: Clinical Status: Published Publish Date: 2017 About this Guideline : This nursing Best Practice Guideline (BPG) is intended to replace the RNAO BPG Adult Asthma Care (...) Guidelines for Nurses: Promoting Control of Asthma (2004) and its supplement (2007). It is to be used by nurses and other members of the interprofessional health-care team to enhance the quality of their practice pertaining to the assessment and management of adult asthma, ultimately improving clinical and health outcomes through the use of evidence-based practices. This Guideline aims to assist nurses and other health-care providers help persons with asthma achieve asthma control, thereby minimizing

Registered Nurses' Association of Ontario2017